ArticleReviews in cardiovascular medicine2025
Construction and Validation of a Prediction Model for Killip Classes II-IV During Hospitalisation in Patients With Acute ST-segment Elevation Myocardial Infarction.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To perform a comprehensive assessment of the predictive value of soluble growth stimulator gene 2 protein (sST2) in predicting in-hospital Killip classes II-IV among patients with acute ST-segment elevation myocardial infarction (STEMI). This study aimed to provide more precise prognostic insights for informed clinical decision-making. Methods: A retrospective cohort study was performed. The clinical records of STEMI patients admitted to Tianjin TEDA International Cardiovascular Hospital and who received primary percutaneous coronary intervention (PPCI) within 24 hours of symptom onset from July 2021 to March 2023 were analyzed. Statistical methodologies, including univariate and multivariate analyses, were applied to identify potential risk factors associated with the development of in-hospital Killip classes II-IV and to construct a reliable prediction model. Results: Among a total of 232 enrolled STEMI patients, 50 experienced Killip classes II-IV during their hospitalisation. Compared to those with Killip class I, the Killip class II-IV patients presented with significantly elevated sST2 concentrations and a higher heart rate (HR) at the first visit. In contrast, the left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate (eGFR) values in these patients were significantly lower. Multivariate logistic regression analysis revealed that an sST2 level >77.3 ng/mL (odds ratio (OR) = 2.813, 95% confidence interval (CI): 1.201-6.586, Conclusion: In STEMI patients undergoing PPCI, the combination of sST2, first-visit HR, LVEF, and eGFR can effectively predict patients with Killip classes II-IV during hospitalisation, which may contribute to early intervention and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.